Explore our workshops at Corporate Workshop Day - November 6, 2019
Promega will be presenting three workshops at the AMP 2019 Corporate Workshop Day, November 6, 2019. Join us to learn about the many ways our solutions can be used for your research. By attending a workshop and visiting us at booth #3035 to do a short activity you will be entered twice to win a pair of Beats Noise Canceling Headphones.
Past, present and future advances in MSI testing
8:00 - 8:50am | Room 343
Presented by: Jeff Bacher, Senior Research Scientist, Promega Corporation
With the recent discovery that cancers exhibiting microsatellite instability (MSI) are more likely to respond to certain types of immunotherapy, there is a growing need to develop reliable methods to determine MMR status for all cancers. This presentation will cover both basic and advanced topics for characterizing MSI status of tumor tissues and cell-free circulating tumor DNA from liquid biopsies using PCR-capillary electrophoresis, Next Generation Sequencing, and IHC approaches. The development and use of first, second, and third generation MSI analysis and associated technologies will be discussed.
Screening for Mismatch Repair Deficiency in the era of Immunotherapy. A Single Institution Experience and Lessons Learned.
9:00 - 9:50am | Room 343
Presented by: Dr. Mahesh M. Mansukhani, MD, Associate Professor of Pathology and Cell Biology, Director, Laboratory of Personalized Genomic Medicine, Columbia University Irving Medical School
Following the approval of Pembrolizumab – and subsequently ipilimumab - for mismatch-repair deficient (dMMR) or microsatellite instability-high (MSI-H) tumors, the Department of Pathology and Columbia University Irving Medical Center adopted a policy of reflex testing of tumors for dMMR and MSI with oncologist input, selecting tumor types for testing at diagnosis, with testing of all metastatic/recurrent tumors. The talk will discuss our experience with testing over 2000 tumors with this approach, including the rationale for parallel testing, concordance of assays, logistical issues, and lessons learned. Illustrative examples will be presented.
Development and Validation of a Novel Diagnostic Test for Non-Alcoholic Steatohepatitis (NASH)
10:00 - 10:50am | Room 343
Presented by: Pierre Chaumat, Executive Vice President, Biomarker Development, Genfit & M. Robert Pawlak, Ph.D., M.S., Principal Scientist, Genomics, Covance Central Laboratory Services
Approximately 25-30% of the global population has non-alcoholic fatty liver disease. Between 11-40% will progress to non-alcoholic steatohepatitis (NASH), where inflammation and fibrosis increase the risk of disease progression. Genfit’s “NIS4” test is a promising assay that identifies patients with moderate to advanced fibrosis who should be considered for NASH therapeutic clinical trials. NIS4 is an algorithm-based test that incorporates the values of four circulating markers. This workshop will highlight the miR-34a-5p assay, a major component of the NIS4 test and it will focus on Genfit’s assay development and its independent validation at Covance.
Join us in the exhibit hall at booth #3035 to see our workflows in action. Let us know where your pain points arise & we’ll help to show you how our solutions can make sure you avoid any misadventures with your sample. Plus, if you chat with one of our representatives about your research you'll be entered to win a pair of Beats Noise Canceling Headphones. We look forward to speaking and collaborating with you!
- Thursday, November 7
- 11:30am – 4:30pm – Exhibit Hall Open
- 5:45pm – 7:00pm – Welcome Reception in the Exhibit Hall
- Friday, November 8
- 9:00am – 4:00pm – Exhibit Hall Open
- Saturday, November 9
- 9:00am – 1:30pm – Exhibit Hall Open